Sanofi - Aventis Groupe: Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy